Sonoma Pharmaceuticals Inc 最大收入来源是 Human Care,在最近的收益报告中收入为 10,110,000。就地区而言, Europe 是 Sonoma Pharmaceuticals Inc 的主要市场,收入为 4,781,000。
Sonoma Pharmaceuticals Inc 是否盈利?
否,根据最新的财务报表,Sonoma Pharmaceuticals Inc 的净亏损为 $0
Sonoma Pharmaceuticals Inc 有负债吗?
否,Sonoma Pharmaceuticals Inc 的负债为 0
Sonoma Pharmaceuticals Inc 的流通股有多少?
Sonoma Pharmaceuticals Inc 的总流通股为 0
关键数据
前收盘价
$1.15
开盘价
$1.12
当日区间
$1.12 - $1.17
52周范围
$0.8501 - $6.91
交易量
21.1K
平均成交量
174.3K
股息收益率
--
每股收益(TTM)
-1.89
市值
$3.9M
什么是 SNOA?
Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. The company is headquartered in Boulder, Colorado and currently employs 168 full-time employees. The company went IPO on 2007-01-26. The firm is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. The company offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.